GlassScriptPhysician profile
Christina S Michael
NPI 1053369058
$3,020.41
in general payments reported to CMS, 2019-2025
24 companies · $800 in 2025
The $800 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2020: $173 · 2021: $558 · 2022: $269 · 2023: $198 · 2024: $724 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,722.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $848.92 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $262.15 | 2019-2025 | Repatha, Repatha, Otezla |
| Pfizer INC. | $229.86 | 2019-2025 | |
| Abbvie INC. | $193.46 | 2019-2023 | |
| Esperion Therapeutics, INC. | $187.96 | 2020-2021 | |
| Renovia INC | $178.57 | 2021 | |
| Novo Nordisk INC | $145.34 | 2019-2022 | |
| Amarin Pharma, INC. | $114.34 | 2019-2021 | |
| Alk-Abello, INC | $110.43 | 2025 | Neffy |
| Astellas Pharma US INC | $101.75 | 2019-2025 | Veozah |
| Exact Sciences Corporation | $98.51 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $95.49 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $91.15 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $57.14 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $56.89 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $42.66 | 2025 | Fluad, Flucelvax |
| Abbott Laboratories | $39.49 | 2019-2022 | |
| Inspire Medical Systems, INC. | $35.99 | 2024 | Inspire |
| Lilly USA, LLC | $26.58 | 2025 | Mounjaro, Zepbound |
| Ibsa Pharma INC. | $24.99 | 2022 | |
| Therapeuticsmd, INC. | $23.16 | 2019 | |
| Glaxosmithkline, LLC. | $19.75 | 2023 | Shingrix, Arexvy |
| Ultragenyx Pharmaceutical INC. | $19.42 | 2022 | |
| Watermark Medical, INC. | $16.41 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Michael listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.